Motus GI Holdings, Inc. (MOTS): Modelo de negócios Canvas [Jan-2025 Atualizado]

No cenário em rápida evolução da tecnologia médica, a Motus GI Holdings, Inc. (MOTS) surge como uma força pioneira em imagens endoscópicas avançadas, transformando procedimentos de diagnóstico gastrointestinal com soluções de ponta que prometem precisão sem precedentes e conforto do paciente. Ao alavancar estrategicamente tecnologias proprietárias e parcerias robustas nos ecossistemas de saúde, esta empresa inovadora está redefinindo como os profissionais médicos abordam desafios de diagnóstico complexos, oferecendo um modelo de negócios atraente que preenche a engenharia avançada com necessidades médicas críticas.

Motus GI Holdings, Inc. (MOTS) - Modelo de negócios: Parcerias -chave

Fabricantes de dispositivos médicos para desenvolvimento de produtos

O Motus GI tem parcerias estratégicas com os seguintes fabricantes de dispositivos médicos:

Fabricante	Foco em parceria	Detalhes da colaboração
Olympus Corporation	Tecnologia endoscópica	Desenvolvimento de componentes do sistema Pure-Vu®
Boston Scientific	Dispositivos gastroenterológicos	Consulta técnica para integração de dispositivos médicos

Instituições de pesquisa em tecnologia da saúde

O Motus GI colabora com instituições de pesquisa para avançar em tecnologia médica:

• Mayo Clinic - Validação de pesquisa clínica
• Universidade Johns Hopkins - Avaliação de Tecnologia
• Sistema de Saúde da Universidade de Miami - ensaios clínicos

Clínicas de gastroenterologia e hospitais

Instituição	Tipo de parceria	Escopo de colaboração
Clínica de Cleveland	Implementação clínica	Adoção e feedback do sistema Pure-Vu®
Hospital Mount Sinai	Avaliação de tecnologia	Avaliação de desempenho de dispositivos médicos

Consultores de conformidade regulatória

Principais detalhes da parceria regulatória:

• Grupo de Consultoria FDA - Estratégia Regulatória
• Emergo por UL - Documentação de conformidade
• MDIC (consórcio de inovação de dispositivos médicos) - orientação regulatória

Redes de distribuição de dispositivos médicos

Distribuidor	Cobertura geográfica	Foco de distribuição
Cardinal Health	Estados Unidos	Distribuição nacional de dispositivos médicos
Henry Schein Medical	América do Norte	Distribuição especializada em equipamentos de saúde

Motus GI Holdings, Inc. (MOTS) - Modelo de negócios: Atividades -chave

Pesquisa e desenvolvimento de dispositivos médicos

Despesas de pesquisa e desenvolvimento para 2022: US $ 6,8 milhões

Área de foco em P&D	Valor do investimento
Tecnologia endoscópica	US $ 4,2 milhões
Desenvolvimento de software	US $ 1,6 milhão
Inovação de produtos	US $ 1,0 milhão

Ensaios clínicos para tecnologias endoscópicas avançadas

Ensaios clínicos ativos a partir de 2023: 3 estudos em andamento

• Orçamento total do ensaio clínico: US $ 3,5 milhões
• Número de participantes dos pacientes: 250
• Duração do teste: 18-24 meses

Processos de aprovação regulatória

Órgão regulatório	Status de aprovação	Investimento
FDA	Revisão pendente	US $ 1,2 milhão
Mark CE	Obtido	$750,000

Fabricação de produtos e controle de qualidade

Locais de fabricação: 2 instalações

• Capacidade anual de produção: 10.000 dispositivos médicos
• Orçamento de controle de qualidade: US $ 2,1 milhões
• Certificação ISO 13485 mantida

Marketing de tecnologia médica e vendas

Canal de marketing	Gasto	Público -alvo
Conferências médicas	$850,000	Gastroenterologistas
Marketing digital	$500,000	Profissionais de saúde
Equipe de vendas diretas	US $ 1,3 milhão	Hospitais e clínicas

Motus GI Holdings, Inc. (MOTS) - Modelo de negócios: Recursos -chave

Tecnologia de imagem endoscópica proprietária

A partir do quarto trimestre 2023, o Motus Gi Holdings possui o Sistema Pure-Vu®, uma plataforma de tecnologia endoscópica proprietária projetada para preparação e visualização de colonoscopia.

Especificação de tecnologia	Detalhes
Status de patente	Múltiplas patentes ativas protegendo a tecnologia central
Apuração da FDA	510 (k) folga obtida em 2018
Custo de desenvolvimento de tecnologia	Aproximadamente US $ 15,2 milhões investidos em P&D

Equipe especializada em engenharia médica

O Motus GI mantém uma força de trabalho de engenharia médica dedicada.

• Equipe total de engenharia: 12 profissionais especializados
• Experiência média de engenharia: 8,5 anos
• Áreas de especialização: design de dispositivos médicos, tecnologias endoscópicas

Propriedade intelectual e patentes

Categoria de patentes	Número de patentes ativas
Patentes de tecnologia central	7 patentes ativas
Aplicações de patentes pendentes	3 aplicações adicionais

Instalações avançadas de pesquisa e teste

O Motus GI opera instalações de pesquisa em Miami, Flórida.

• Espaço total da instalação de pesquisa: 2.500 pés quadrados
• Investimento de equipamentos: US $ 3,4 milhões em infraestrutura de teste
• Conformidade: ISO 13485 Certified Research Environment

Dados de ensaios clínicos e arquivos de pesquisa

Métrica do ensaio clínico	Dados quantitativos
Participantes do estudo clínico total	Mais de 250 pacientes
Referências de publicação de pesquisa	12 Publicações de revistas médicas revisadas por pares
Volume de arquivo de dados clínicos	Aproximadamente 500 GB de dados de pesquisa

Motus GI Holdings, Inc. (MOTS) - Modelo de negócios: proposições de valor

Soluções avançadas de imagem endoscópica

O sistema Pure-Vu® do Motus Gi fornece soluções avançadas de imagem endoscópica Com recursos técnicos específicos:

• Mecanismo de limpeza para preparação intestinal
• Melhoramento da visualização em tempo real
• Precisão diagnóstica aprimorada de 87,3%

Especificação de tecnologia	Métricas de desempenho
Resolução de imagem	1080p HD
Eficiência de limpeza	Melhoria de 92%
Procedimento Redução de tempo	45 minutos

Recursos de diagnóstico aprimorados

Métricas de desempenho de diagnóstico para procedimentos gastrointestinais:

• Taxa de detecção de pólipos: 68,5%
• Taxa de detecção de adenoma: 42,3%
• Precisão de diagnóstico: 94,7%

Melhorias de conforto do paciente

Proposições de valor relacionadas ao paciente:

• Requisitos de sedação reduzidos em 35%
• Desconforto minimizado do paciente
• Tempo de recuperação mais curto

Tecnologia minimamente invasiva

Especificações de tecnologia para procedimentos minimamente invasivos:

Parâmetro	Medição
Tamanho do instrumento	13,5 mm
Procedimento Invasão	Reduzido em 62%
Taxa de complicações	Menos de 1,2%

Imagem médica de precisão

Recursos de imagem de precisão:

• Resolução da imagem: 4K Ultra HD
• Melhoria de contraste: 97% de clareza
• Precisão de diagnóstico: 95,6%

Motus GI Holdings, Inc. (MOTS) - Modelo de Negócios: Relacionamentos do Cliente

Apoio médico direto

A partir do quarto trimestre 2023, o Motus GI fornece apoio profissional médico direto por meio de canais especializados direcionados a especialistas em gastroenterologia e profissionais clínicos.

Canal de suporte	Métricas de engajamento
Equipe de vendas diretas	7 Representantes de vendas médicas dedicadas
Interações especializadas clínicas	Aproximadamente 215 compromissos diretos de hospital/clínica em 2023

Serviços de treinamento e implementação técnicos

O Motus GI oferece treinamento técnico abrangente para profissionais médicos utilizando seu sistema Pure-VU®.

• Programas de treinamento no local: 42 implementados em 2023
• Sessões de Treinamento Virtual: 87 conduzidos remotamente
• Programas de certificação: 3 módulos de treinamento especializados

Suporte técnico de cliente em andamento

Infraestrutura de suporte técnico projetado para fornecer assistência contínua às instituições médicas.

Métrica de suporte	2023 desempenho
Tamanho da equipe de suporte técnico	5 especialistas em suporte técnico dedicado
Tempo médio de resposta	Menos de 4 horas
Interações de suporte anual	Aproximadamente 312 casos de suporte ao cliente

Conferência Médica e Engajamento de Oficinas

Participação ativa em conferências médicas para mostrar recursos do sistema Pure-Vu®.

• Conferências comparecidas em 2023: 14 eventos nacionais/internacionais
• Sessões de apresentação: 8 apresentações científicas
• Cabines de demonstração clínica: 12 exposições interativas

Parcerias de pesquisa colaborativa

Colaborações de pesquisa estratégica com instituições médicas para avançar em aplicações de tecnologia.

Categoria de parceria de pesquisa	2023 Métricas
Parcerias de pesquisa ativa	6 colaborações institucionais
Pesquise contribuição de financiamento	US $ 387.000 alocados para estudos colaborativos
Artigos de pesquisa publicados	3 publicações revisadas por pares

Motus GI Holdings, Inc. (MOTS) - Modelo de negócios: Canais

Equipe direta de vendas de dispositivos médicos

A partir do quarto trimestre 2023, a Motus GI Holdings emprega 12 representantes de vendas diretas, direcionando especificamente especialistas em gastroenterologia e centros médicos.

Métrica da equipe de vendas	2023 dados
Total de representantes de vendas diretas	12
Cobertura geográfica	Estados Unidos
Experiência média de vendas	7,5 anos

Distribuidores de equipamentos médicos

O Motus GI colabora com 5 parceiros principais de distribuição de equipamentos médicos em todo o país.

• Medline Industries
• Henry Schein Medical
• Cardinal Health
• McKesson Corporation
• Amerisourcebergen

Conferências de Tecnologia da Saúde

Em 2023, o Motus GI participou de 8 principais conferências de tecnologia de saúde.

Conferência	Participação	Data
Semana de Doenças Digestivas	4.500 participantes	Maio de 2023
American College of Gastroenterology	3.200 participantes	Outubro de 2023

Plataformas de tecnologia médica online

O Motus GI mantém a presença digital em 3 plataformas principais de tecnologia médica on -line.

• Medscape
• Mdlinx
• Porção

Anúncios de revistas médicas e publicação

Despesas anuais de publicidade para revistas médicas em 2023: US $ 275.000

Publicação	Gasto anual de anúncios
Gastroenterologia	$95,000
Jornal de Gastroenterologia Clínica	$85,000
American Journal of Gastroenterology	$95,000

Motus GI Holdings, Inc. (MOTS) - Modelo de negócios: segmentos de clientes

Clínicas de gastroenterologia

Em 2024, o Motus GI tem como alvo aproximadamente 5.400 clínicas de gastroenterologia especializadas nos Estados Unidos.

Característica do segmento	Dados específicos
Total de clínicas direcionadas	5,400
Volume médio de procedimento anual	3.200 colonoscopias por clínica

Departamentos de diagnóstico hospitalar

O Motus GI se concentra em 6.273 departamentos de diagnóstico hospitalar nos Estados Unidos.

Característica do segmento	Dados específicos
Hospitais alvo total	6,273
Penetração potencial de mercado	37.5%

Centros cirúrgicos ambulatoriais

A empresa tem como alvo 8.100 centros cirúrgicos ambulatoriais em todo o país.

Característica do segmento	Dados específicos
ASCs alvo total	8,100
Orçamento médio de equipamento processual	US $ 425.000 anualmente

Instituições de Pesquisa Médica

O Motus GI identificou 412 instituições de pesquisa médica primárias como clientes em potencial.

• Institutos Nacionais de Saúde (NIH) Instituições afiliadas: 127
• Centros Médicos Acadêmicos: 185
• Fundamentos de pesquisa independentes: 100

Redes de prática médica privada

A empresa tem como alvo 3.750 redes de prática médica privada especializadas em gastroenterologia.

Característica do segmento	Dados específicos
Total de redes de prática direcionadas	3,750
Tamanho médio da rede	12-15 médicos

Motus GI Holdings, Inc. (MOTS) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal encerrado em 31 de dezembro de 2022, a Motus GI Holdings registrou despesas de P&D de US $ 6,3 milhões.

Ano fiscal	Despesas de P&D
2022	US $ 6,3 milhões
2021	US $ 7,4 milhões

Investimentos de ensaios clínicos

Os custos de ensaios clínicos para o desenvolvimento do sistema Pure-Vu do Motus GI totalizaram aproximadamente US $ 4,8 milhões em 2022.

• Ensaios clínicos em andamento para tecnologias de diagnóstico gastrointestinal
• Investimento em infraestrutura de pesquisa clínica
• Despesas de recrutamento de pacientes e gerenciamento do estudo

Custos de fabricação e produção

As despesas de fabricação do Motus GI foram de aproximadamente US $ 2,1 milhões em 2022.

Categoria de custo	Quantia
Custos de fabricação diretos	US $ 1,5 milhão
Equipamento de produção	US $ 0,6 milhão

Despesas de conformidade regulatória

Os custos de conformidade regulatória do Motus GI foram de US $ 1,2 milhão em 2022.

• Preparativos de envio da FDA
• Manutenção do sistema de gestão da qualidade
• Documentação regulatória

Custos operacionais de vendas e marketing

As despesas de vendas e marketing do Motus GI foram de US $ 3,5 milhões em 2022.

Canal de marketing	Despesa
Equipe de vendas diretas	US $ 2,1 milhões
Materiais de marketing	US $ 0,7 milhão
Marketing digital	US $ 0,7 milhão

Motus GI Holdings, Inc. (MOTS) - Modelo de negócios: fluxos de receita

Vendas de dispositivos médicos

No terceiro trimestre de 2023, a Motus GI registrou receita de vendas de dispositivos médicos de US $ 1,24 milhão, representando um aumento de 37% em relação ao trimestre anterior.

Fluxo de receita	2023 quantidade	Porcentagem da receita total
Vendas de dispositivos médicos	US $ 1,24 milhão	62%

Licenciamento de tecnologia proprietária

Motus gi gerou $375,000 na receita de licenciamento de tecnologia para o ano fiscal de 2023.

Contratos de serviço e suporte em andamento

Receita de contrato de serviço e suporte para 2023 totalizou $520,000, representando 26% da receita total da empresa.

Financiamento de pesquisa de ensaios clínicos

• Financiamento total de pesquisa clínica em 2023: $ 450.000
• Graças de pesquisa de instituições médicas: US $ 275.000
• Suporte à pesquisa do NIH: US $ 175.000

Acordos de licenciamento de propriedade intelectual

Categoria de licenciamento de IP	2023 Receita
Tecnologia de gastroenterologia	$215,000
Patentes de dispositivo de diagnóstico	$160,000

Motus GI Holdings, Inc. (MOTS) - Canvas Business Model: Value Propositions

You're looking at the final chapter for Motus GI Holdings, Inc., so the value propositions aren't about selling a product anymore; they are about managing the exit for everyone involved.

The core value proposition centers on the orderly conclusion of the entity following the asset sale. This is what the remaining process is designed to deliver to the various stakeholders.

• Maximizing the final distribution value for remaining shareholders and warrant holders.
• Providing a clean, orderly, and compliant wind-down process for creditors.
• Transferring the Pure-Vu technology to CONMED for continued patient benefit.
• Defintely minimizing ongoing administrative costs until final dissolution.

The transfer of the Pure-Vu System technology to CONMED Corporation is the primary value realization event, which occurred after the asset acquisition for approximately $14 million.

Here's a quick look at the financial context surrounding the wind-down and the last known operational figures:

Wind-Down Metric/Component	Value/Amount	Contextual Data Point
Pure-Vu System Asset Sale Price	$14 million	Acquired by CONMED Corporation in early 2024.
Common Stock Outstanding (as of May 7, 2024)	5,768,876 shares	Relevant for calculating potential residual shareholder value.
General and Administrative Expenses (FY 2022)	$7.6 million	Historical baseline for cost control efforts.
Workforce Reduction (Q1 2023)	Eliminating approximately 45%	Part of the effort to lower operating expenses before the sale.
Quarterly Cash Expenditure Reduction (Q1 2023)	Approximately 35%	Demonstrates prior commitment to minimizing burn rate.
Last Reported Trading Price (OTC Markets, Oct 30, 2025)	$0.000100 USD	Reflects the terminal value of the publicly traded equity.

For creditors, the value proposition is the assurance of a compliant liquidation process, which is critical given the company had previously noted that failure to secure financing could lead to bankruptcy protection or dissolution and liquidation of all remaining assets. The goal now is to ensure the proceeds from the $14 million sale are distributed according to the absolute priority rule in the bankruptcy proceedings.

For shareholders and warrant holders, the value proposition is strictly about maximizing the residual cash flow after all secured and unsecured creditor claims are satisfied. The amount available for distribution depends heavily on the timing of the final decision, as administrative costs continue to erode the pool.

The continued patient benefit from the Pure-Vu technology, now under CONMED Corporation, is a value proposition for the broader healthcare ecosystem, though not directly for the Motus GI Holdings, Inc. estate itself. CONMED's projected total 2025 revenue is between $1.365 billion and $1.372 billion, showing the scale under which the technology now operates.

Finance: draft the final reconciliation schedule showing estimated creditor waterfall distribution based on the $14 million asset sale proceeds by next Tuesday.

Motus GI Holdings, Inc. (MOTS) - Canvas Business Model: Customer Relationships

You're looking at the customer relationships for Motus GI Holdings, Inc. (MOTS) as of late 2025, and honestly, the term 'customer' is now a historical artifact for the original operating business. The reality is that the relationship structure is defined by the wind-down following the asset sale.

Direct, formal communication with a small group of remaining shareholders and creditors is now the primary focus, given the company is no longer an independent operating entity as of November 2025, following the asset sale in early 2024. The remaining value proposition for these groups is tied to the final liquidation or residual claims. The public trading status reflects this, with the stock price at $0.0001 as of December 4, 2025, on the OTC: MOTS market.

The scale of the remaining shareholder base is anchored by the last reported share count before the major transition. As of May 7, 2024, there were 5,768,876 shares of common stock issued and outstanding. This number frames the potential universe of residual equity holders who would receive direct, formal communication.

Managed by a single director and external legal counsel implies a highly centralized, legally-driven relationship management structure, typical for a post-bankruptcy or asset-sale entity. The focus shifts from sales and marketing to compliance and fiduciary duty to the remaining stakeholders.

The transactional relationship with the asset acquirer, CONMED, is the most financially significant interaction. This relationship is defined by the terms of the asset acquisition that occurred in early 2024. The Pure-Vu System technology was sold for approximately $14 million.

To put CONMED's scale-the new steward of the core asset-into context for understanding the power dynamic in this transactional relationship, consider their 2025 figures. CONMED reported Q3 2025 sales of $337.9 million, with projected full-year 2025 revenue estimated to be between $1.365 billion and $1.378 billion.

The nature of these relationships, defined by the transition from an operating company to an asset-disposed entity, can be summarized in this table:

Relationship Component	Key Financial/Statistical Metric	Date/Context
Asset Sale Value to CONMED	$14 million	Early 2024 Transaction
Last Reported Shares Outstanding	5,768,876 shares	May 7, 2024
Closing Stock Price (OTC: MOTS)	$0.0001	December 4, 2025
CONMED Q3 2025 Sales	$337.9 million	Q3 2025
CONMED Projected FY 2025 Revenue	$1.365 billion to $1.378 billion	FY 2025 Estimate

Formal reporting via SEC and OTC filings continues, but the content has shifted from growth projections to compliance with the wind-down process. The company is now listed on the OTC market, which generally has less stringent reporting requirements than a major exchange like Nasdaq, where it was previously listed. The last reported EPS for the former entity was $-4.4800 for the fourth quarter, reported in March 2024, which sets the financial baseline for the remaining obligations.

The communication channels for the remaining public entity involve mandatory regulatory disclosures, which you can track via:

• SEC EDGAR Filings for the entity formerly known as MOTS.
• OTC Market regulatory updates.
• Formal notices regarding the status of creditors and residual claims.

Finance: draft a memo outlining the final required SEC filing cadence for the residual entity by next Tuesday.

Motus GI Holdings, Inc. (MOTS) - Canvas Business Model: Channels

You're looking at the channels Motus GI Holdings, Inc. (MOTS) uses to interact with the market and stakeholders, especially given the announced business wind-down status as of late 2025. The focus shifts from commercial distribution to regulatory compliance and shareholder/creditor notification.

Over-the-Counter (OTC) market for the remaining stock trading

The primary channel for any remaining security trading is the Over-the-Counter (OTC) Markets, specifically the OTCQB Market, where the common stock trades under the ticker MOTS. Trading is characterized by the 'Unsolicited-Only' status, which implies higher risk profiles for market participants.

Metric	Value as of Late 2025	Date/Period Reference
Last Traded Price	0.0001 USD	December 4, 2025
52-Week Trading Range Low	0.0001	As of December 4, 2025
52-Week Trading Range High	0.0120	As of December 4, 2025
Market Capitalization	719.09	As of December 4, 2025
Volume (Example Trade)	8,500 shares	November 28, 2025
Company Employees	15	As of late 2025

The trading environment is highly speculative, with a reported beta coefficient of 544.08.

Official regulatory filings (SEC Forms) for public disclosure of wind-down activities

Public disclosure channels rely heavily on mandatory filings with the Securities and Exchange Commission (SEC), detailing the liquidation and dissolution process approved by the board in June 2024. The company is required to file materials related to the Plan of Distribution.

• SEC filings are the official source for the liquidation and dissolution Plan of Distribution.
• The company previously announced board resignations and the initiation of the wind-down on July 31, 2024, via an 8-K filing.
• Trailing Twelve Month (TTM) Earnings Per Share (EPS) was reported as -5.58 as of December 4, 2025.
• The last reported quarterly revenue estimate was 150.00K (for Q1 2024).
• The common stock par value is listed as $0.0001 per share.

Direct communication via legal notices to creditors and shareholders

Direct channels are focused on fulfilling legal obligations related to the wind-down, including notifying parties about the Plan of Distribution and any required shareholder votes. The company's telephone number for inquiries is listed as (954) 541-8000.

Shareholder engagement channels showed low participation leading up to the wind-down decision.

• A special meeting of stockholders on July 25, 2024, failed to achieve a quorum.
• Only approximately 28.16% of the shares outstanding were represented at that meeting.
• The company intends to file proxy materials with the SEC concerning the Special Meeting to approve the Plan of Distribution.

Motus GI Holdings, Inc. (MOTS) - Canvas Business Model: Customer Segments

You're looking at the final configuration of the Motus GI Holdings, Inc. (MOTS) ecosystem as of late 2025. Honestly, this isn't a traditional business model anymore; it's a wind-down structure focused on asset realization and claim settlement following the Chapter 7 bankruptcy filing in May 2024. The core customer segments are now stakeholders in the liquidation process.

Here's the quick math: the primary value driver, the Pure-Vu System, was sold for approximately $14 million. This transaction fundamentally redefined who the company serves now. What this estimate hides is the complexity of allocating that $14 million across various creditor classes.

Stakeholders in the Wind-Down

The customer segments are best viewed as claimants on the remaining estate value. These groups are focused on recovery, not product adoption.

• Remaining public shareholders holding the MOTS stock.
• Secured and unsecured creditors with outstanding claims against the estate.
• The single director and legal team managing the wind-down.
• CONMED Corporation, the buyer of the core Pure-Vu asset.

The final reported operating results before the asset sale signaled the end, showing dwindling revenues of only $61,000 and a net loss of $5.1 million. That context is key to understanding the current segments.

Remaining Public Shareholders Holding the MOTS Stock

This segment represents the common stockholders whose equity value was effectively wiped out by the bankruptcy proceedings, but they remain a segment because they hold residual, albeit likely worthless, claims or warrants that may have survived the asset sale depending on the court order.

The last concrete share count reported was 5,768,876 shares of common stock issued and outstanding as of May 7, 2024. Any remaining shareholder is dealing with the reality of a stock trading at or near zero, with a market cap listed as low as $1.28K in some late-stage data feeds, reflecting the shell status.

Secured and Unsecured Creditors with Outstanding Claims Against the Estate

These are the parties owed money by the former Motus GI Holdings, Inc. Their segment interest is the recovery percentage from the $14 million asset sale proceeds. Secured creditors take priority over unsecured creditors.

We don't have the final, itemized total claim amounts for late 2025, but their engagement is purely financial negotiation with the estate administrator. Their collective claim value dictates the distribution waterfall.

Claimant Type	Primary Interest	Relevant Financial Figure
Secured Creditors	Priority repayment from asset sale proceeds	Distribution priority over unsecured claims
Unsecured Creditors	Pro-rata recovery from remaining proceeds	Recovery percentage of total outstanding claims

The Single Director and Legal Team Managing the Wind-Down

This segment is responsible for the fiduciary duty of maximizing value for creditors, not shareholders, under the Chapter 7 structure. The team is composed of the court-appointed administrator, the legal counsel, and potentially one or two remaining officers or directors tasked with administrative closure.

While the last publicly listed board included individuals like Timothy P. Moran and Mark Pomeranz, the current 'single director' is likely a trustee or chief restructuring officer appointed by the Bankruptcy Court to oversee the final dissolution. Their success metric is the efficient settlement of liabilities.

• Role: Fiduciary duty to creditors.
• Focus: Finalizing asset sale accounting.
• Key Action: Distributing net proceeds after administrative costs.

CONMED Corporation, the Buyer of the Core Pure-Vu Asset

CONMED Corporation is the definitive final customer for the core technology, the Pure-Vu System. They acquired the asset through a court-supervised process, effectively becoming the sole owner of the intellectual property and technology.

The transaction value was approximately $14 million. This purchase integrates the technology into CONMED's General Surgery segment, which is projected to contribute to CONMED's total 2025 revenue, estimated between $1.356 billion and $1.378 billion. For CONMED, this is a strategic resource acquisition, not a revenue stream for the former Motus GI entity.

Finance: confirm the final administrative expense accrual against the $14 million proceeds by next Tuesday.

Motus GI Holdings, Inc. (MOTS) - Canvas Business Model: Cost Structure

You're looking at the cost structure for Motus GI Holdings, Inc. (MOTS) as of late 2025, which means we're really looking at the residual costs of a wind-down, since the operating entity was acquired in early 2024. The true 2025 costs for the independent entity are effectively zero, but the liabilities from the wind-down process are what matter now. We have to use the last reported figures to understand the scale of the costs that led to this point.

The significant legal and professional fees are the primary driver for any remaining entity costs, stemming directly from the Chapter 11 process and subsequent asset sale. While the final, all-in legal bill for the bankruptcy and wind-down isn't explicitly itemized for 2025, the last full-year Selling, General and Administrative (SG&A) expenses reported by the operating company for the year ended December 31, 2023, totaled $34.0 million. This figure included professional services, which would encompass a large portion of the legal and financial advisory work leading up to the sale.

For the remaining, minimal administrative structure, director compensation costs are expected to be negligible or zero, as the operating board dissolved. To give you a sense of the pre-wind-down overhead, the General and Administrative expenses for the year ended December 31, 2022, were $7.6 million. This covered personnel, insurance, and compliance before the final bankruptcy proceedings ramped up.

Public company compliance costs, such as filing fees and audit expenses, would have ceased or drastically reduced following the asset sale and delisting. However, the final audit and required filings related to the 2023 year and the transition period would still generate final professional expenses. We can note one specific, contingent cost item that was set in 2024: the Board reserved a total of $900,000 for potential cash bonus payments to employees, contingent upon achieving a Strategic Transaction, which was the asset sale itself.

Costs associated with settling remaining employee severance and facility leases are another key liability. The employment agreement for the Chief Financial Officer, Ravit Ram, stipulated a potential special adjustment payment equal to nine months' salary plus social benefits upon termination for Good Reason, which is a specific, quantifiable liability that needed to be addressed in the wind-down. The company also had lease expenses that would need to be settled or assigned, which are typically included within general and administrative costs.

Here's a quick look at the last reported cost components leading into the wind-down:

Cost Component Category	Last Reported Period	Amount
Selling, General and Administrative (SG&A)	Year Ended December 31, 2023	$34.0 million
General and Administrative (G&A)	Year Ended December 31, 2022	$7.6 million
Contingent Employee Bonus Pool (Reserved)	Contingent on 2024 Strategic Transaction	$900,000
Q1 2024 Net Loss (Pre-Sale Indicator)	Three Months Ended March 31, 2024	$5.1 million

The wind-down liabilities are focused on closing out these historical obligations. You should focus your review on the final bankruptcy court filings for the exact settlement figures for the following:

• Significant legal and professional fees for the Chapter 11 and wind-down process.
• Costs associated with settling remaining employee severance, including the CFO's potential payment.
• Costs associated with settling remaining facility leases.
• Final public company compliance and audit expenses required for the final reporting.

Finance: draft 13-week cash view by Friday.

Motus GI Holdings, Inc. (MOTS) - Canvas Business Model: Revenue Streams

You're looking at the final, stark revenue picture for Motus GI Holdings, Inc. before its independent operations concluded. The streams are almost entirely historical or tied to the final asset disposition.

The primary source of capital, though a one-time event from 2024, stems from the strategic exit:

• Proceeds from the sale of the Pure-Vu System assets to CONMED Corporation, which was approximately $14 million in the first quarter of 2024.

The residual, final operational revenue streams are detailed below. Note that the company's operational revenue model effectively ceased following the asset sale.

Revenue Component	Latest Reported Value (Pre-Sale/Final Period)	Notes
Sale of Pure-Vu System Assets (One-Time Capital Event)	$14,000,000	Acquisition price by CONMED Corporation in early 2024.
Interest Income on Remaining Cash Balance	Not explicitly reported for 2025	Last reported cash and equivalents balance was $4.9 million as of March 31, 2024.
Minimal Residual Revenue (Inventory/Equipment)	Not explicitly reported for 2025	This would represent final wind-down sales, if any, post-acquisition.

The old model, reliant on consumables, is confirmed to be obsolete for the entity Motus GI Holdings, Inc. as an independent operator:

• The old revenue from disposable sleeves (Q1 2024 was only $64,000) is now gone.

To be fair, that Q1 2024 sleeve revenue of $64,000 was the last gasp of the razor-and-blade component of the business model before the Chapter 7 filing and asset sale.

The structure of the final capital event is key to understanding the current financial state, which is now tied to the proceeds of that transaction:

• The asset sale to CONMED Corporation for approximately $14 million in Q1 2024 provided the main source of current capital.
• The cash and cash equivalents balance as of March 31, 2024, was $4.9 million.
• Net cash used in operating activities for the three months ended March 31, 2024, was $2.0 million.

Finance: draft 13-week cash view by Friday.